These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35200536)

  • 21. A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study.
    Lexchin J
    J Pharm Policy Pract; 2021 Oct; 14(1):93. PubMed ID: 34711285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
    Chabot I; Rocchi A
    Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study.
    Mooghali M; Mitchell AP; Skydel JJ; Ross JS; Wallach JD; Ramachandran R
    BMJ Med; 2024; 3(1):e000802. PubMed ID: 38596814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
    Jaksa A; Louder A; Maksymiuk C; Vondeling GT; Martin L; Gatto N; Richards E; Yver A; Rosenlund M
    Value Health; 2022 Dec; 25(12):1967-1976. PubMed ID: 35760714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis.
    Graili P
    Appl Health Econ Health Policy; 2023 Jul; 21(4):673-681. PubMed ID: 36609982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 33. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
    Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
    Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
    Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
    Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HTA Barriers for Conditional Approval Drugs.
    Mills M
    Pharmacoeconomics; 2023 May; 41(5):529-545. PubMed ID: 36821044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. USING THE INTEGRATE-HTA GUIDANCE: EXPERIENCE FROM CADTH.
    Bond K; Weeks L
    Int J Technol Assess Health Care; 2017 Jan; 33(5):591-596. PubMed ID: 29143698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada.
    Vanderpuye-Orgle J; Erim D; Qian Y; Boyne DJ; Cheung WY; Bebb G; Shah A; Pericleous L; Maruszczak M; Brenner DR
    Oncol Ther; 2022 Jun; 10(1):195-210. PubMed ID: 35230672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
    Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
    Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.